Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

por Thakurta, A, Gandhi, A K, Waldman, M F, Bjorklund, C, Ning, Y, Mendy, D, Schafer, P, Lopez-Girona, A, Lentzsch, S, Schey, S A, Calle, Y, Chelliah, R, Orlowski, R Z, Madan, A, Avet-Loiseau, H, Chopra, R
Publicado 2014

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF...

por Bjorklund, C C, Lu, L, Kang, J, Hagner, P R, Havens, C G, Amatangelo, M, Wang, M, Ren, Y, Couto, S, Breider, M, Ning, Y, Gandhi, A K, Daniel, T O, Chopra, R, Klippel, A, Thakurta, A G
Publicado 2015

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

por Lopez-Girona, A, Mendy, D, Ito, T, Miller, K, Gandhi, A K, Kang, J, Karasawa, S, Carmel, G, Jackson, P, Abbasian, M, Mahmoudi, A, Cathers, B, Rychak, E, Gaidarova, S, Chen, R, Schafer, P H, Handa, H, Daniel, T O, Evans, J F, Chopra, R
Publicado 2012

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

por Lopez-Girona, A, Mendy, D, Ito, T, Miller, K, Gandhi, A K, Kang, J, Karasawa, S, Carmel, G, Jackson, P, Abbasian, M, Mahmoudi, A, Cathers, B, Rychak, E, Gaidarova, S, Chen, R, Schafer, P H, Handa, H, Daniel, T O, Evans, J F, Chopra, R
Publicado 2012

Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses

por Blumberg, L. J., Humphries, J. E., Jones, S. D., Pearce, L. B., Holgate, R., Hearn, A., Cheung, J., Mahmood, A., Del Tito, B., Graydon, J. S., Stolz, L. E., Bitonti, A., Purohit, S., de Graaf, D., Kacena, K., Andersen, J. T., Christianson, G. J., Roopenian, D. C., Hubbard, J. J., Gandhi, A. K., Lasseter, K., Pyzik, M., Blumberg, R. S.
Publicado 2019